104 related articles for article (PubMed ID: 17933133)
41. [Abnormalities of chromosome 17 in myeloid malignancies with complex chromosomal abnormalities].
Zhu Y; Xu W; Liu Q; Pan J; Qiu H; Wang R; Qiao C; Jiang Y; Zhang S; Fan L; Zhang J; Shen Y; Xue Y; Li J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Oct; 25(5):579-82. PubMed ID: 18841577
[TBL] [Abstract][Full Text] [Related]
42. [Bacteremia in hematological malignant disorders].
Hammerstrøm J; Røym AL; Gran FW
Tidsskr Nor Laegeforen; 2008 Aug; 128(15):1655-9. PubMed ID: 18704131
[TBL] [Abstract][Full Text] [Related]
43. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
44. The INK4-ARF (CDKN2A/B) locus in hematopoiesis and BCR-ABL-induced leukemias.
Williams RT; Sherr CJ
Cold Spring Harb Symp Quant Biol; 2008; 73():461-7. PubMed ID: 19028987
[TBL] [Abstract][Full Text] [Related]
45. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Branford S; Seymour JF; Grigg A; Arthur C; Rudzki Z; Lynch K; Hughes T
Clin Cancer Res; 2007 Dec; 13(23):7080-5. PubMed ID: 18056186
[TBL] [Abstract][Full Text] [Related]
46. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
47. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
[TBL] [Abstract][Full Text] [Related]
48. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
So CC; Ma ES; Wan TS; Yip SF; Chan LC
Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
[No Abstract] [Full Text] [Related]
50. [International Congress of the American Society of Hematology, Philadelphia, 6-10 December 2002].
Veyssier-Belot C;
Rev Med Interne; 2003 Jul; 24(7):485-90. PubMed ID: 12829227
[No Abstract] [Full Text] [Related]
51. Monitoring treatment results in patients with chronic myelogenous leukemia.
Radich JP
Clin Adv Hematol Oncol; 2008 Aug; 6(8):577-8, 586. PubMed ID: 18820599
[No Abstract] [Full Text] [Related]
52. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Tanaka R; Kimura S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
[TBL] [Abstract][Full Text] [Related]
53. False-positive pregnancy tests in females of reproductive potential receiving lenalidomide in the United States.
Castaneda C; Minton N; Mezo M; Hirsch D; Phillips L; Sheehan P; McWilliams R; Chan-Liston M; Bwire R; Freeman J
Leuk Lymphoma; 2018 Apr; 59(4):1025-1026. PubMed ID: 28792264
[No Abstract] [Full Text] [Related]
54. Hematology-oncology. Hematology-Oncology Workgroup, Legislative Task Force on Cancer in Texas.
Gardner FH; Alperin JB; Belli JA; Farley PC; Frenkel EP; Redman JR; Roodman GD; Sears DA; Trowbridge AA
Tex Med; 1987 Sep; 83(9 Pt 2):59-71. PubMed ID: 3672407
[No Abstract] [Full Text] [Related]
55. [Treatment of hematological malignancies with low molecular weight compounds].
Kizaki M
Nihon Rinsho; 2007 Jan; 65 Suppl 1():60-6. PubMed ID: 17474395
[No Abstract] [Full Text] [Related]
56. Current awareness in hematological oncology.
Hematol Oncol; 1993; 11(4):209-18. PubMed ID: 8144135
[No Abstract] [Full Text] [Related]
57. Current awareness in hematological oncology.
Hematol Oncol; 1994; 12(1):41-50. PubMed ID: 8194841
[No Abstract] [Full Text] [Related]
58. [Standard chemotherapy of hematological cancers].
Mitsuma A; Naoe T
Nihon Naika Gakkai Zasshi; 2009 Aug; 98(8):1880-6. PubMed ID: 19894349
[No Abstract] [Full Text] [Related]
59. Current awareness in hematological oncology.
Hematol Oncol; 1993; 11(1):51-8. PubMed ID: 8325626
[No Abstract] [Full Text] [Related]
60. Current awareness in hematological oncology.
Hematol Oncol; 1995; 13(2):109-18. PubMed ID: 7797193
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
